• AC Immune (ACIU) Phase 1/2 Results of ACI-24 for Alzheimer's Disease

       (0 reviews)

    Clinical and Regulatory
    Event Type: Phase 1/2 Results
    Timing: H2 2016
    Designation(s): None

    This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
    FDA special designations may increase the likelihood of success and decrease the time to approval.
    Learn More

    Disease and Treatment
    Disease: Neurology
    Indication: Alzheimer's Disease
    Lead Indication?: No
    Treatment Name: ACI-24

    Likelihood of event success varies depending on disease, treatment and lead indication classification.
    Learn More

    Company Information
    Co. Name: AC Immune
    Stock Symbol: ACIU
    Shares Traded: NASDAQ

    The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
    Learn More

    Event Status
    Event Outcome: Ongoing
    Event Discussion: Forums
    Event Announcement(s): https://www.sec.gov/Archives/edgar/data/1651625/000119312516718500/d16439d424b4.htm
    Partnership: No

    Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
    Learn More

    Detailed Event Description from Company Announcement



    Two of our other clinical product candidates, ACI-24 and ACI-35, are being developed using our SupraAntigen platform and target AD through active immunization, where the immune system is stimulated to make its own antibodies against pathological proteins:


        ACI-24 is our wholly-owned anti-Abeta vaccine candidate currently in a Phase 1/2a study. We expect to complete this study and announce top line results in the second half of 2016. ACI-24 is also being studied in a Phase 1 clinical study in patients with Down syndrome, a population that is at high risk for AD.



      Report Event

    User Feedback

    There are no reviews to display.